Company intelligence / Profile preview

Hepasome Pharmaceuticals

Ownership: Private
Development stage: Other

Overview

The company developed an oral and subcutaneous formulation of interferon alpha for hepatitis C. A Phase II proof-of-concept study was conducted comparing efficacy and safety to pegylated interferon plus ribavirin in chronic hepatitis C patients. The trial's status remains unknown, with no recent results or ongoing development reported.

Therapeutic areas: Infectious Diseases
Modalities: ProteinBiologic
Industry: Biotech

Beyond the preview

Go deeper on Hepasome Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hepasome Pharmaceuticals.

Explore the full profile